Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1121-1140 of 1,307 trials

Ulcerative Colitis: Encapsulated Stool Microbiome Study

We are investigating whether long-term treatment with encapsulated stool microbiome can improve symptoms in people with active ulcerative colitis. This study compares the treatment to a placebo to assess its effectiveness.

Active Ulcerative Colitis≤3 monthsConfirmation phase (III)Investigational MedicinesGastroenterologyInfectious Diseases

Chronic Hepatitis Delta: BJT-778 vs Bulevirtide

We are studying a new treatment called brelovitug for chronic hepatitis delta infection to see if it works better and is safer than the current treatment, bulevirtide. We also want to understand how it affects patients' quality of life.

Chronic Hepatitis D Infection1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHepatologyInfectious Diseases

Multiple System Atrophy: Lu AF82422 Study

We are testing the medication Lu AF82422 to see if it can slow disease progression in people with Multiple System Atrophy. The study will also look at its effects on overall health and quality of life.

Multiple System Atrophy1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Ozone Treatment for Numbness from Chemotherapy

We are studying whether adding ozone therapy helps reduce numbness and tingling in patients with chemotherapy-induced nerve damage. The trial also looks at how this treatment affects overall quality of life and costs.

Chemotherapy-Induced Peripheral Neuropathy6-12 monthsEfficacy phase (II)Confirmation phase (III)>20 visitsStandard MedicinesInternal MedicineNeurologyOncology

Multiple Myeloma: Isatuximab Treatment Study

We are studying a new treatment combination for elderly patients with newly diagnosed multiple myeloma who cannot undergo a transplant. The goal is to see if this approach improves disease control and safety compared to standard treatments.

Newly Diagnosed Multiple Myeloma in Elderly Patients>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Crohn's Disease: Cellvizio Imaging Study

We are testing a new imaging technique during surgery for Crohn's disease to help identify healthy tissue margins. This may improve surgical outcomes by ensuring enough healthy tissue is removed.

Crohn's Disease>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyInternal Medicine

NSTEMI Treatment: Aspirin vs. Aspirin and Fondaparinux

We are comparing the effects of aspirin alone to a combination of aspirin and fondaparinux in patients with NSTEMI. This study aims to see which treatment is more effective and safer before invasive procedures.

Non-ST-Elevation Myocardial Infarction (NSTEMI)>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Colorectal Cancer: MK-1084 Treatment Study

We are testing a new treatment combining MK-1084, cetuximab, and chemotherapy for patients with advanced colorectal cancer. The goal is to see if this combination is safer and more effective than standard treatments.

Metastatic Colorectal CancerKRAS Mutation>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Unruptured Intracranial Aneurysms: Low-Dose Aspirin and Blood Pressure Management

We are studying whether a treatment plan with low-dose aspirin and strict blood pressure control can lower the risk of aneurysm rupture or growth in patients with unruptured intracranial aneurysms. This trial compares this approach to standard care to see if it offers better outcomes.

Unruptured Intradural Aneurysm>2 yearsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesCardiologyNeurology

Sinusitis Treatment: Azithromycin Study

We are testing whether a three-month course of azithromycin improves quality of life for adults with idiopathic purulent oedematous sinusitis. The study will compare its effects to a placebo and evaluate treatment tolerance.

Bacterial SinusitisChronic Sinusitis>2 yearsConfirmation phase (III)Investigational MedicinesOtolaryngology

Higher Risk Myelodysplastic Syndrome: Lisaftoclax with Azacitidine

We are studying whether the combination of Lisaftoclax and azacitidine is more effective than a placebo with azacitidine for adults newly diagnosed with higher risk myelodysplastic syndrome. The trial will also assess safety and patient-reported outcomes.

Higher Risk Myelodysplastic SyndromeConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementHematologyOncology

Juvenile Psoriatic Arthritis: Deucravacitinib Study

We are testing a new medication, deucravacitinib, in children and teens aged 5 to 18 with Juvenile Psoriatic Arthritis. The study aims to see if it works better than a placebo and to ensure it is safe and easy to take.

Systemic Juvenile Idiopathic Arthritis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPediatricsRheumatology

Psoriatic Arthritis: JNJ-77242113 Study

We are testing a new medication for people with active psoriatic arthritis who have used other biologic treatments. The study aims to see if it can reduce symptoms better than a placebo.

Psoriatic Arthritis1-2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyRheumatology

Advanced Liver Cancer: CS1003 with Lenvatinib

We are studying a new treatment combined with lenvatinib for people with advanced liver cancer. The trial compares this combination to a placebo with lenvatinib to see which is more effective and safe.

Unresectable Advanced Liver Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteHepatologyOncology

Recombinant Factor VIIa for Acute Hemorrhagic Stroke

We are studying whether giving a new treatment quickly after a bleeding stroke can improve recovery for patients. This trial focuses on those who have had spontaneous bleeding in the brain and aims to measure their functional outcomes.

Hemorrhagic Stroke>2 yearsConfirmation phase (III)Investigational MedicinesPartially RemoteHematologyNeurology

Ovarian Cancer Relapse: Hyperthermic Intraperitoneal Chemotherapy Study

We are investigating whether adding HIPEC improves survival for patients with ovarian cancer relapse compared to standard treatment. The study also looks at quality of life, side effects, and other important factors.

Ovarian Epithelial Cancer Relapse>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Sacubitril/Valsartan for Arrhythmogenic Right Ventricular Cardiomyopathy

We are studying whether sacubitril/valsartan can help prevent disease progression in patients with ARVC. This trial aims to assess its effects on heart tissue changes.

Arrhythmogenic Cardiomyopathy>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiology

Prostate Cancer: BMS-986365 vs. Standard Treatment

We are comparing a new medication, BMS-986365, to standard treatments for men with metastatic castration-resistant prostate cancer. The study aims to see if the new drug can better delay disease progression and improve overall health.

Metastatic Castration-resistant Prostate Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Chronic Inflammatory Demyelinating Polyradiculoneuropathy: TAK-881 vs. HYQVIA

We are comparing two medications to see if TAK-881 works similarly to HYQVIA in adults with CIDP. This study may help determine the best treatment options for managing this condition.

Chronic Inflammatory Demyelinating Polyradiculoneuropathy1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNeurology

Chronic Obstructive Pulmonary Disease: Tezepelumab Study

We are investigating whether tezepelumab can help adults with moderate to very severe COPD experience fewer flare-ups and improve their lung function and quality of life compared to a placebo.

Chronic Obstructive Pulmonary Disease (COPD)1-2 yearsConfirmation phase (III)16-20 visitsStandard MedicinesCost ReimbursementPartially RemotePulmonology